Speculation about a takeover play for Cytokinetics isn’t going away, with Amgen the latest company to be linked to the company and its highly-anticipated cardiovascular dr
With M&A news coming thick and fast on the first day of the JP Morgan Healthcare conference in San Francisco, attendees were left hanging as proceedings closed with no
Shares in US biotech Cytokinetics have popped after a report that its aficamten drug improved symptoms in people with a rare and progressive form of heart disease.
In this instalment of Health Innovators, EiC Jonah Comstock sits down virtually with Fady Malik, EVP of research and development at Cytokinetics and Steve Heitner, the company’s VP of clinical rese
There’s been a big disappointment for people with amyotrophic lateral sclerosis (ALS), after Cytokinetics said it was halting a trial of its resedemtiv candidate following
Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.